Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jan;51(2):307-308.
doi: 10.1111/apt.15600.

Editorial: effects of vedolizumab during pregnancy in the CONCEIVE study

Affiliations
Editorial

Editorial: effects of vedolizumab during pregnancy in the CONCEIVE study

Rachel W Winter. Aliment Pharmacol Ther. 2020 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:941-950.
    1. Bar-Gil Shitrit A, Ben Yaʼacov A, Livovsky DM, et al. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol. 2019;114:1172-1175.
    1. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease (IBD) in pregnancy clinical care pathway - a report from the american gastroenterological association IBD parenthood project working group. Gastroenterology. 2019;156:1508-1524.
    1. Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51:129-138.
    1. Nørgård B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease activity in pregnant women with crohn’s disease and birth outcomes: A regional danish cohort study. Am J Gastroenterol. 2007;102:1947-1954.

Substances